Atara Biotherapeutics, Inc. Price Today
Atara Biotherapeutics, Inc.
ATRA
Healthcare
$126.38M
💰
Market Cap
0
💸
Price to Earnings
$-3.0
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Hold Consensus
Buy |
7 |
Strong Buy |
3 |
Hold |
3 |
Sell |
1 |
Strong Sell |
1 |
ATRA Price Forecast Target
1.2 👉 31.0 +2380%
ATRA EPS Forecast
-3.0 👉 -2.0 +-34%
Financials
Profit Margin
0 %
Revenue Growth
-98.1 %
Dividend
$ 0
Held Percent
2.6% - Insiders
107.6% - Institutions
-10.2% - Public
Major Fund Holders
-
💰 Baupost Group, Inc,.(The) LLC $15.7M
-
💰 Wasatch Advisors LP $13.3M
-
💰 Blackrock Inc. $13.3M
-
💰 JP Morgan Chase & Company $12.4M
-
💰 Vanguard Group Inc $11.2M
Stock Ideas
Bruce Berkowitz Portfolio
Bruce Berkowitz, the esteemed founder of Fairholme, has established himself as a prominent figure in the investment world with his exceptional portfolio strategy. Since its inception in 1999, Fairholme has grown into a formidable $19 billion mutual …
Ken Fisher Portfolio
Ken Fisher is a prominent American investment analyst, author, and the founder of Fisher Investments, a global investment firm managing billions of dollars in assets for individual and institutional clients. As a highly successful investor and fina…
Carl Icahn Portfolio
With a staggering net worth exceeding $16 billion, Icahn has made a lasting impact on the stock market as the founder and manager of Icahn Enterprises. Known as a 'corporate raider,' Icahn has gained fame for his relentless pursuit of undervalued co…
Andreas Halvorsen Portfolio
Andreas Halvorsen is a Norwegian billionaire investor, hedge fund manager, and the founder of Viking Global Investors, a large hedge fund with over $50 billion in assets under management. He is known for his long-term, value-oriented investment appr…📮FAQ
Some Frequently Asked Questions.
The Atara Biotherapeutics, Inc. industry is Biotechnology
The Atara Biotherapeutics, Inc. sector is Healthcare
The Atara Biotherapeutics, Inc. forecasted predicted Price to Earnings PE ratio is -0.6
The Atara Biotherapeutics, Inc. Price to Earnings PE ratio is 0
The Market Capitalization of Atara Biotherapeutics, Inc. is $126.38M
There are total of 77909318 float shares with 107.6% held by Institutions and 2.6% held by insiders
The MAtara Biotherapeutics, Inc. forecasted Earnings per Share EPS is $-2.0
The Atara Biotherapeutics, Inc. Earnings per Share EPS is -3.0
The Atara Biotherapeutics, Inc. company has $63573000 gross profits with 0 profit margins
The Atara Biotherapeutics, Inc. Earnings Growth is 0% with 0% quarterly earnings growth
The Atara Biotherapeutics, Inc. Revenue is $6863000 with -0.981 revenue growth
The price target for Atara Biotherapeutics, Inc. stock is $31.0 for the high target and $1.4 for the low target
The consensus analyst recommendations for Atara Biotherapeutics, Inc. is Hold, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Atara Biotherapeutics, Inc. is Hold, with the following breakdown:
- Buy: 7
- Strong Buy: 3
- Hold: 3
- Sell: 1
- Strong Sell: 1
The Beta of Atara Biotherapeutics, Inc. is 1.0
The dividend of Atara Biotherapeutics, Inc. is $0
The dividend yield of Atara Biotherapeutics, Inc. is 0%
The biggest institutional and mutual fund holders of Atara Biotherapeutics, Inc. stock are
- Baupost Group, Inc,.(The) LLC
- Wasatch Advisors LP
- Blackrock Inc.
- JP Morgan Chase & Company
The Atara Biotherapeutics, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0